Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9) vaccine candidate for the prevention of avian flu. Research on the drug has progressed rapidly, moving from viral gene sequencing, to vaccine candidacy, to multiple animal studies, and now, just three months after the gene sequence was obtained, into a clinical trial.
Novavax (NVAX +1.9%) says it's begun enrollment for Phase 1 clinical trials of its A(H7N9)...
From other sites
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jun 6, 2014)
at CNBC.com (Apr 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs